ArticleDiscover oncology2026
An exosome-related gene signature predicts prognosis, immune suppression, and therapeutic sensitivity in luminal breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLuminal breast cancer has a high incidence and significant heterogeneity. Exosomes, as key mediators of intercellular communication, are involved in the tumor process, but the related genes in Luminal breast cancer regarding prognosis and mechanism remain unclear.
methodsThis study integrated a total of 1251 Luminal breast cancer samples from the TCGA and GEO databases. Differential expression analysis and Cox regression were used to screen out prognostic-related exosomal genes, and a multivariate Cox risk prognostic model was constructed. Kaplan-Meier survival analysis and time-dependent ROC curves were used to evaluate the model performance. Further immunological analysis, gene set enrichment analysis (GSEA), transcription factor/ceRNA regulatory network construction, and drug sensitivity analysis were conducted.
resultsA total of 4 prognostic-related exosomal genes (LCN2, RRAS2, LRG1, LTF) were identified. Based on this, a risk model was constructed that can effectively distinguish high-risk and low-risk patients, and the overall survival of the high-risk group was significantly shorter. Immunological analysis showed that the high-risk group had increased M2 Macrophage infiltration and accompanied by immune function inhibition. GSEA suggested that the high-risk group was enriched in tumor progression-related pathways such as DNA replication and homologous recombination. Drug sensitivity analysis indicated that the high-risk group showed higher sensitivity to PI3K inhibitors and chemotherapy drugs.
conclusionLCN2, RRAS2, LRG1, and LTF can be used as prognostic markers for Luminal breast cancer, related to immune suppression and tumor progression, and the high-risk group is more sensitive to PI3K inhibitors and chemotherapy drugs, providing potential targets for precision treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.